Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers

The objective of this project is to determine in a non-invasive manner (fecal samples) the predictive value of the intestinal microbiota and the presence of genotoxin-producing bacteria on the response to neoadjuvant treatment in rectal cancer. This could lead to a better understanding and selection of patients for personalized treatment in rectal cancer.

Trial Details

NCT ID
NCT04103567
Phase
NA
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Biological collection
Locations (sample)
  • Montpellier, Hérault, France|43.61093,3.87635
  • Clermont-Ferrand, Puy De Dôme, France|45.77969,3.08682

Key Eligibility Criteria

  • Histologically proven lower and mid-rectal adenocarcinoma at clinical stage II and III
  • Patient is to receive neoadjuvant treatment (radiochemotherapy or chemotherapy or radiotherapy). Induction chemotherapy such as folfox or folfirino…
  • Patient who has signed the informed consent of the study
  • Male or female ≥ 18 years old

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →